Replies to post #535692 on NorthWest Biotherapeutics Inc (NWBO)

[Fireman02360]

So please tell me why the total market for solid tumors is relevant if NWBO has not proven any efficiency outside any other indication other than GBM?

Are you a Doctor that can confirm there are no similarities between all solid tumors and how DCVax MOA may work on these other cancers? If not you are not qualified to make this statement. While I agree NW Bio will not be solid at full valuation, the fact that DCVax MAY work on other solid tumors would command a premium over just the GBM Market. I dont subscribe to the $50-100B valuations just yet, but discounting what the drug may do on other indications without having the proper background to make such assumptions is just plan stupid. There are some very smart folks at BP that may know this answer, and if the answer is even a "maybe", then we can start adding digits over what the current GBM Market will command. This is the sole premise why BP acquires smaller companies that are only in Phase 2 trials on uproven drugs = The "maybe". If every acquisition was made after what is knownand right before approval, and without the "maybe", the number of acquisitions would drop considerably and the cost of acquisitions would rise, and BP would not be able to expand pipelines as quick. That's obviously not the case in bio-land.....BP is always hungry to deepen their pipe-lines, and as such will pay pretty large premiums on the "maybe" to accomplish this.

-Fireman

[hump4]

Tell that to people who are dying. They will pay out of pocket for a good chance of survival. It's called off label prescription.